MA44060A - Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations - Google Patents
Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisationsInfo
- Publication number
- MA44060A MA44060A MA044060A MA44060A MA44060A MA 44060 A MA44060 A MA 44060A MA 044060 A MA044060 A MA 044060A MA 44060 A MA44060 A MA 44060A MA 44060 A MA44060 A MA 44060A
- Authority
- MA
- Morocco
- Prior art keywords
- bispecific
- tl1a
- tnf
- alpha
- antigen proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562268432P | 2015-12-16 | 2015-12-16 | |
US201662333063P | 2016-05-06 | 2016-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44060A true MA44060A (fr) | 2018-10-24 |
Family
ID=59057540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA044060A MA44060A (fr) | 2015-12-16 | 2016-12-14 | Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations |
Country Status (24)
Country | Link |
---|---|
US (2) | US11104745B2 (fr) |
EP (1) | EP3390444A1 (fr) |
JP (1) | JP7263007B2 (fr) |
KR (1) | KR20180099723A (fr) |
CN (1) | CN109311971A (fr) |
AU (2) | AU2016370659B2 (fr) |
BR (1) | BR112018012096A2 (fr) |
CA (1) | CA3008267A1 (fr) |
CL (3) | CL2018001596A1 (fr) |
CO (1) | CO2018007355A2 (fr) |
CR (1) | CR20180365A (fr) |
EA (1) | EA201891322A1 (fr) |
IL (1) | IL259847A (fr) |
JO (1) | JO3816B1 (fr) |
MA (1) | MA44060A (fr) |
MX (1) | MX2018007424A (fr) |
PH (1) | PH12018501284A1 (fr) |
SG (2) | SG11201804857WA (fr) |
TN (1) | TN2019000275A1 (fr) |
TW (1) | TWI799368B (fr) |
UA (1) | UA124305C2 (fr) |
UY (1) | UY37027A (fr) |
WO (1) | WO2017106383A1 (fr) |
ZA (1) | ZA201904491B (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062960A2 (fr) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire |
WO2013044298A1 (fr) | 2011-09-30 | 2013-04-04 | Cephalon Australia Pty Ltd | Anticorps contre tl1a et leurs utilisations |
UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
KR102464372B1 (ko) | 2016-03-17 | 2022-11-04 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
CN118240830A (zh) | 2016-10-26 | 2024-06-25 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
EP3456738A1 (fr) | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Variantes d'anticorps |
EP3735270A1 (fr) * | 2018-01-05 | 2020-11-11 | Modernatx, Inc. | Polynucléotides codant pour des anticorps anti-virus du chikungunya |
CA3098374A1 (fr) | 2018-04-25 | 2019-10-31 | Prometheus Biosciences, Inc. | Anticorps anti-tl1a optimises |
CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
CN114375339A (zh) * | 2019-05-14 | 2022-04-19 | 普罗米修斯生物科学公司 | Tl1a患者选择方法、系统和装置 |
BR112022000416A2 (pt) * | 2019-07-11 | 2022-03-03 | Wuhan Yzy Biopharma Co Ltd | Anticorpo biespecífico, composição farmacêutica, conjugado, polinucleotídeo, célula e usos do anticorpo biespecífico |
CA3147103A1 (fr) | 2019-07-19 | 2021-01-28 | Oncoresponse, Inc. | Anticorps immunomodulateurs et leurs methodes d'utilisation |
BR112022007720A2 (pt) | 2019-10-24 | 2022-08-23 | Prometheus Biosciences Inc | Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos |
CN113121696A (zh) * | 2019-12-31 | 2021-07-16 | 周易 | Fab改造诱导形成的双特异性抗体及其制备方法和用途 |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
US20230159649A1 (en) * | 2020-04-02 | 2023-05-25 | La Jolla Institute For Immunology | Methods and combinations for dual targeting of tnf family members |
WO2021236997A2 (fr) * | 2020-05-20 | 2021-11-25 | The Trustees Of Columbia University In The City Of New York | Anticorps neutralisants puissants contre le sras-cov-2, leur génération et leurs utilisations |
CA3183367A1 (fr) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Molecules de liaison a l'antigene ciblant le sars-cov-2 |
JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗aベータ抗体 |
EP4200338A1 (fr) * | 2020-08-20 | 2023-06-28 | Amgen Inc. | Protéines de liaison à un antigène avec un disulfure non canonique dans la région fab |
KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997034631A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
JP2002510644A (ja) | 1998-04-03 | 2002-04-09 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物 |
BR0009323A (pt) | 1999-03-25 | 2002-01-08 | Knoll Gmbh | Anticorpos humanos que ligam a il-12 humana e métodos para a produção |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
AU783682B2 (en) | 1999-08-04 | 2005-11-24 | Amgen, Inc. | Fhm, a novel member of the TNF ligand supergene family |
RU2377253C2 (ru) | 2002-12-02 | 2009-12-27 | Амген Фремонт,Инк. | Антитела, специфичные к фактору некроза опухолей, и их применение |
US20080233119A2 (en) | 2003-08-20 | 2008-09-25 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
US9068003B2 (en) | 2007-01-10 | 2015-06-30 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
JP5745854B2 (ja) | 2007-11-13 | 2015-07-08 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Tl1aに対するヒト化抗体 |
EP3663318A1 (fr) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique |
WO2009131239A1 (fr) | 2008-04-25 | 2009-10-29 | Kyowa Hakko Kirin Co Ltd | Anticorps polyvalent stable |
CN102361883A (zh) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-1/抗-c-Met抗体 |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
WO2012088302A2 (fr) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Protéines de liaison à une demi-immunoglobuline et leurs utilisations |
US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
JP2014533929A (ja) | 2011-09-23 | 2014-12-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 5t4およびcd3に対する二重特異的結合性分子 |
WO2013044298A1 (fr) | 2011-09-30 | 2013-04-04 | Cephalon Australia Pty Ltd | Anticorps contre tl1a et leurs utilisations |
WO2013177101A2 (fr) | 2012-05-22 | 2013-11-28 | Bristol-Myers Squibb Company | Anticorps bispécifiques et procédés les utilisant |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US10077298B2 (en) | 2012-11-28 | 2018-09-18 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
AU2013371957B2 (en) | 2013-01-02 | 2018-10-25 | Ichnos Sciences SA | Antibodies that bind to TL1A and their uses |
TW201444867A (zh) | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗tnf-抗il-17雙特異性抗體 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
WO2014144357A1 (fr) | 2013-03-15 | 2014-09-18 | Merck Patent Gmbh | Anticorps bispécifiques tétravalents |
EP2968541A4 (fr) * | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Complexes multispécifiques multivalents et monovalents et leurs utilisations |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
MY182271A (en) | 2013-11-13 | 2021-01-18 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
US20160052006A1 (en) | 2013-11-22 | 2016-02-25 | Sheila S. Pirtle | Spray Bottle |
-
2016
- 2016-09-15 CR CR20180365A patent/CR20180365A/es unknown
- 2016-12-14 MX MX2018007424A patent/MX2018007424A/es unknown
- 2016-12-14 EA EA201891322A patent/EA201891322A1/ru unknown
- 2016-12-14 SG SG11201804857WA patent/SG11201804857WA/en unknown
- 2016-12-14 US US16/062,096 patent/US11104745B2/en active Active
- 2016-12-14 WO PCT/US2016/066722 patent/WO2017106383A1/fr active Application Filing
- 2016-12-14 CA CA3008267A patent/CA3008267A1/fr active Pending
- 2016-12-14 KR KR1020187020093A patent/KR20180099723A/ko not_active Application Discontinuation
- 2016-12-14 TN TNP/2019/000275A patent/TN2019000275A1/en unknown
- 2016-12-14 MA MA044060A patent/MA44060A/fr unknown
- 2016-12-14 UA UAA201806971A patent/UA124305C2/uk unknown
- 2016-12-14 JP JP2018531447A patent/JP7263007B2/ja active Active
- 2016-12-14 SG SG10201912002YA patent/SG10201912002YA/en unknown
- 2016-12-14 EP EP16822583.7A patent/EP3390444A1/fr active Pending
- 2016-12-14 AU AU2016370659A patent/AU2016370659B2/en active Active
- 2016-12-14 CN CN201680082044.0A patent/CN109311971A/zh active Pending
- 2016-12-14 BR BR112018012096-0A patent/BR112018012096A2/pt active Search and Examination
- 2016-12-15 UY UY0001037027A patent/UY37027A/es unknown
- 2016-12-15 JO JOP/2016/0261A patent/JO3816B1/ar active
- 2016-12-16 TW TW105141920A patent/TWI799368B/zh active
-
2018
- 2018-06-06 IL IL259847A patent/IL259847A/en unknown
- 2018-06-14 CL CL2018001596A patent/CL2018001596A1/es unknown
- 2018-06-14 PH PH12018501284A patent/PH12018501284A1/en unknown
- 2018-07-13 CO CONC2018/0007355A patent/CO2018007355A2/es unknown
-
2019
- 2019-07-09 ZA ZA2019/04491A patent/ZA201904491B/en unknown
-
2021
- 2021-05-05 CL CL2021001179A patent/CL2021001179A1/es unknown
- 2021-07-19 US US17/379,968 patent/US20220213226A1/en active Pending
-
2023
- 2023-09-01 CL CL2023002597A patent/CL2023002597A1/es unknown
-
2024
- 2024-01-29 AU AU2024200534A patent/AU2024200534A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44060A (fr) | Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations | |
MA52273A (fr) | Protéines de liaison à un antigène anti-trem2 et leurs utilisations | |
MA44885A (fr) | Protéines de liaison bispécifiques et leurs utilisations | |
FR23C1011I1 (fr) | Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations | |
MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
MA42808A (fr) | Anticorps de liaison à l'il-8 et leurs utilisations | |
DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
DK3332006T5 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
MA43551A (fr) | Protéines immunomodulatrices à variants du ligand icos et leurs utilisations | |
MA43164A (fr) | Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations | |
DK3274370T3 (da) | Anti-ceacam6-antistoffer og anvendelser deraf | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
DK3368572T3 (da) | Anti-pd-1-antistoffer og -sammensætninger | |
MA43552A (fr) | Protéines immunomodulatrices à variants de cd80 et leurs utilisations | |
MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
MA42821A (fr) | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
DK3247722T3 (da) | Cytomegalovirusantigener og anvendelser deraf |